English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212586
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Splice-site variant in ACSL5: a marker promoting opposing effect on cell viability and protein expression

AuthorsPérez-Núñez, I.; Karaky, Mohamad.; Fedetz, María.; Barrionuevo, C.; Izquierdo, G.; Matesanz, F.; Alcina, Antonio
Issue Date2019
PublisherSpringer Nature
CitationEuropean Journal of Human Genetics (2019)
AbstractLong-chain Acyl-CoA synthetases (ACSLs) activate fatty acids (FAs) by thioesterification with Coenzyme A (CoA), generating FA-CoAs. These products are essential for lipid metabolism and carcinogenesis. In previous study, we identified an intronic variant rs2256368:A>G, whose G allele promotes exon 20 skipping in up to 43% of ACSL5 transcripts but its functional relevance is unclear. Here, we compared the expression of splice (Spl) and nonsplice (NSpl) ACSL5 variants and the effect on cell viability under culture conditions that force cells to metabolize fatty acids. We found that lymphoblastoid cell lines from 1000 Genomes Project, bearing Spl genotypes, showed a reduced expression of total ACSL5 protein due to an inefficient translation of the Spl RNA. These cells impaired growth in cultures with phorbol myristate acetate-ionomycin (PMA-Io) or medium deprived of glucose, while production of reactive oxygen species increased in PMA-Io. Specific ACSL5-isoform transfection in HEK239T (kidney), U87 (astroglioma), and HOG (oligodendrocyte) cells showed the Spl protein to be the causal factor of cell-growth inhibition, despite its reduced protein expression. Our findings indicate that the variant rs2256368:A>G can predict a growth inhibitory activity, caused by the Spl isoform of ACSL5 protein, opposed to the activity of the NSpl. Deep understanding of its functioning might have application in metabolic diseases and cancer.
Publisher version (URL)http://dx.doi.org/10.1038/s41431-019-0414-5
Identifiersdoi: 10.1038/s41431-019-0414-5
issn: 1018-4813
e-issn: 1476-5438
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
s41431-019-0414-5.pdf1,07 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.